Ropes & Gray advised Kailera Therapeutics, Inc. on the transaction. Kailera Therapeutics, Inc. (“Kailera”) announced raising $400 million in Series A financing. Kailera announced its launch...
Kailera Therapeutics’ $400 Million Series A Financing
SK Biopharmaceuticals’ License Agreement with Full-Life Technologies
Ropes & Gray represented SK Biopharmaceuticals on the transaction. SK Biopharmaceuticals announced it has entered into an global licensing agreement with radiotherapy company Full-Life Technologies (“Full-Life”)...
Erasca’s In-Licensing of RAS-Targeting Franchise
Ropes & Gray advised Erasca, Inc. on the deal. Erasca, Inc. (Nasdaq: ERAS), a precision oncology company, announced it has entered into an exclusive license agreement...
Allorion Therapeutics’ Licensing Agreement with Avenzo Therapeutics
Ropes & Gray advised Allorion Therapeutics on the transaction. Allorion Therapeutics (Allorion) announced it entered into a global licensing agreement with Avenzo Therapeutics Inc. (Avenzo) to develop and...